Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$338.91 USD
+5.52 (1.66%)
Updated Jan 10, 2025 04:00 PM ET
After-Market: $338.72 -0.19 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MDGL 338.91 +5.52(1.66%)
Will MDGL be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
Other News for MDGL
RTW INVESTMENTS, LP Acquires Additional Shares in Allurion Technologies Inc
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
SA Asks: Which biotechs are most likely to be acquired near-term?
Madrigal Pharmaceuticals Inc (MDGL) to Present at J.P. Morgan Healthcare Conference
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc